GlassScriptPhysician profile
Rita Gonzalez
NPI 1386208510
$21,825.14
in general payments reported to CMS, 2019-2025
37 companies · $5,349 in 2025
The $5,349 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,082 · 2022: $2,840 · 2023: $4,335 · 2024: $6,219 · 2025: $5,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $95.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,807.51 |
| Education | $95.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,921.48 | 2021-2025 | Enbrel, Otezla, Krystexxa |
| Abbvie INC. | $3,659.12 | 2021-2025 | |
| Janssen Biotech, INC. | $3,127.91 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $2,167.26 | 2021-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,601.55 | 2021-2025 | |
| Pfizer INC. | $1,203.61 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $798.94 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $712.35 | 2021-2024 | Taltz, Zepbound |
| Mallinckrodt Hospital Products INC. | $679.17 | 2023-2025 | Acthar |
| Organon LLC | $430.12 | 2023-2025 | Hadlima, Renflexis, Nexplanon |
| Glaxosmithkline, LLC. | $429.65 | 2021-2025 | Benlysta |
| Horizon Therapeutics Plc | $428.39 | 2021-2023 | Krystexxa |
| Janssen Scientific Affairs, LLC | $365.59 | 2021-2025 | Tremfya |
| Genzyme Corporation | $324.18 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $241.73 | 2021-2024 | Opsumit, Uptravi |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $237.28 | 2021-2025 | Strensiq |
| Ani Pharmaceuticals, INC. | $205.91 | 2022-2025 | Purified Cortrophin Gel |
| Radius Health, INC. | $187.67 | 2023-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.11 | 2023-2025 | Cyltezo, Jascayd, Ofev |
| E.R. Squibb & Sons, L.L.C. | $146.11 | 2021-2025 | Orencia |
| Galderma Laboratories, L.P. | $134.03 | 2022 | |
| Sobi, INC | $100.26 | 2021-2025 | |
| Pacira Therapeutics, INC. | $92.03 | 2021 | |
| Aurinia Pharma U.S., INC. | $72.69 | 2023-2024 | Lupkynis |
| Janssen Pharmaceuticals, INC | $66.82 | 2021 | |
| Genentech USA, INC. | $54.44 | 2021-2025 | Actemra, Rituxan |
| Mylan Institutional INC. | $46.36 | 2023 | Hulio |
| Fresenius Kabi USA, LLC | $41.26 | 2024-2025 | Idacio |
| Teva Pharmaceuticals USA, INC. | $30.93 | 2023-2024 | Truxima |
| Octapharma USA, INC. | $21.46 | 2024 | Octagam Immune Globulin (Human) |
| Kiniksa Pharmaceuticals, LTD. | $21.39 | 2021 | |
| Abbott Laboratories | $19.81 | 2024 | Proclaim |
| Nevro Corp. | $19.02 | 2024 | Senza |
| Scilex Pharmaceuticals INC. | $18.99 | 2024 | |
| Merck Sharp & Dohme LLC | $17.36 | 2021 | |
| Hikma Pharmaceuticals USA | $14.58 | 2021 | |
| Eyevance Pharmaceuticals LLC | $14.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.